mTOR Inhibitors curves showing the percentage of patients exhibiting 0 improvement in rTNSSs or a score of point or less for each nasal symptom by treatment day af-ter treatment with M , F azelastin or placebo . Data are presented as mean proportion of patients for the meta-analysis dataset , and azelastine on overall rTNSSs in patients with moderate-to-severe SAR. Data are presented as least squares mean change from baseline derived by means of ANCOVA minus placebo. The precision of these estimates are in-dicated by the upper bounds of the respective shows the proportion of patients in each treatment group who experienced a 0 or greater reduction in rTNSS over time.

The results highlighted a time advantage of M over FP and aze-lastine monotherapy in producing a clini-cally meaningful reduction in rTN as well as an increased responder rate with M . More patients treated with M also exhibitedplete or nearplete elimination of their symptoms than those treated with F azelastin or placebo . Moreov this effect was also observed days earlier than either monotherapy: up to days faster than FP and up to days faster than azelas-tine . rTNSS change from baseline by baseline patient severity. M  Apixaban provided benes for all patien providing signi antly greater symptom relief than FP or azelastine monotherapy regardless of disease severity . When severity was split by median baseline rTN M was signi antly superior to FP and azelastine in patients with less severe diseas with a greater bene observed in patients with more severe disease pared with both FP or azelastine . When severity was alternatively split by median baseline RQLQ sco M was again superior to FP and azelastine monotherapy in patients with moderate rhinitis  . of vs azelastine) and signi antly superior in patients with severe rhinitis . QoL. Patients were well matched for QoL impairme with overall baseline RQLQ scores of in the M , azelasti and placebo groups and in the FP group.

By day 4, all active treatments signi antly improved patient QoL pared with placebo . DISCUSSION Before M , no clinical development program had dem-onstrated additional bene over currently rmended st-line AR therapies in patients with moderate-to-severe disease. In the present program M demonstrated superior ef acy over intranasal FP and intranasal azelastine monotherapy in patients with AR in a set of randomiz double-bli placebo-controlled clinical studies with active controls by using the same device and formulation. This provides sound clinical eviden for the st ti that intranasal antihistamines and corticoste-roids haveplementary pharmacologic effects on the patho-genesis of AR and satisfy the demands of the Allergic Rhinitis and its Impact on Asthma guidelines  authority requesting high-quality directparison studies. The consistency of the results among the clinical trials and symptoms contributes to the robustness of the data. Adverse events were similar for all active grou and only a few patients experienced.